PRO-C3 biomarker from Nordic Bioscience launched in China

Nordic Bioscience will be launching the PRO-C3 biomarker in China for research use only (RUO) in the first quarter of 2024. This announcement was made by the company on February 7, 2024 in a press release distributed by PRNewswire. Nordic Bioscience is a leading biomarker company known for its extracellular matrix (ECM) biomarker, PRO-C3 (nordicPRO-C3™), which will be available in China through LabCorp. It will remain available exclusively at Nordic Bioscience’s laboratories in Herlev, Denmark for all tests outside of China.
The launch of the PRO-C3 biomarker in China represents a significant advancement for drug developers and scientists in China, as it will provide them with pre-IVD access to this cutting-edge biomarker through LabCorp in Shanghai. The biomarker is particularly relevant for drug development in chronic diseases that have a fibrotic component, including non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and several types of cancer with solid tumors.
The CEO of Nordic Bioscience, Morten A. Karsdal, expressed excitement about the collaboration, stating that it will enable faster and broader access to precision medicine enabled by the PRO-C3 biomarker. He emphasized that this initiative will support drug developers in their efforts to bring new medicines to the market for chronic debilitating diseases in a more cost-effective and timely manner, potentially improving patients’ lives in the future.
The PRO-C3 biomarker quantifies type III collagen formation through blood sample measurements. Moreover, the FDA recently issued a letter of support for future investigation of the PRO-C3 biomarker as a proposed prognostic biomarker in clinical trials of patients with solid tumors, as tumor fibrosis has been found to be associated with aggressive tumor progression and poor overall survival.
The biomarker assay can be measured on Roche’s fully automated cobas® e platform, and its availability for RUO in China will facilitate broader market access. Additionally, the licensing agreement between Nordic Bioscience and Roche will include multiple Nordic Bioscience biomarkers on Roche’s fully automated cobas® e platform over the coming years, paving the way for better research and drug development in chronic diseases.
Nordic Bioscience encourages those interested in learning more about the PRO-C3 biomarker and its availability in China to reach out through its official channels. The company is based in Herlev, Denmark, and specializes in the development of biomarkers using unique neoepitope technology. It combines its experience in biomarker development with preclinical and clinical research to develop biomarkers that provide rapid and objective decision-making for compound selection and development in clinical trials, as well as providing value to patients in a diagnostic setting.
To see photos and logos related to this announcement, please visit:
Photo – https://mma.prnewswire.com/media/2334368/ROCHE_NORDIC_PRO_C3_CHINA.jpg
Logo – https://mma.prnewswire.com/media/2334369/Nordic_Bioscience_Logo.jpg.

Source link



Leave a Reply

Your email address will not be published. Required fields are marked *

Most Viewed

Featured Franchise Opportunity

Arabica Coffee House

Food & Beverage Franchises

$10ˌ000 - $50ˌ000

MilliCare Franchise

Cleaning Franchises, Low Cost Franchises

$10ˌ000 - $50ˌ000